Sukhi Jagpal serves as Chief Financial Officer of the Company. Previously, Mr. Jagpal served as the Chief Financial Officer of QLT Inc., a biotechnology company, from July 2012 to February 2015, where he also served as the Senior Director, Finance and Corporate Controller from January 2011 to June 2012. Mr. Jagpal has also held senior finance positions with Pivotal Corporation, 360networks Inc. and KPMG LLP. Mr. Jagpal is a Chartered Professional Accountant, a Chartered Business Valuator and holds an M.B.A. from Cornell University – S.C. Johnson Graduate School of Management and an M.B.A. from Queens University.
As the Chief Financial Officer of Sierra Oncology Inc, the total compensation of Sukhi Jagpal at Sierra Oncology Inc is $859,428. There are 2 executives at Sierra Oncology Inc getting paid more, with Barbara Klencke having the highest compensation of $971,397.
Sukhi Jagpal is 46, he's been the Chief Financial Officer of Sierra Oncology Inc since 2015. There are 16 older and 1 younger executives at Sierra Oncology Inc. The oldest executive at Sierra Oncology Inc is Robert Pelzer, 66, who is the Independent Chairman of the Board.
Sukhi's mailing address filed with the SEC is C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 8 years, insiders at Sierra Oncology Inc have traded over $0 worth of Sierra Oncology Inc stock and bought 8,528,701 units worth $69,515,388 . The most active insiders traders include Andrew Sinclair, Llp Abingworth, and James N Topper. On average, Sierra Oncology Inc executives and independent directors trade stock every 85 days with the average trade being worth of $21,400,348. The most recent stock trade was executed by William D. Turner on 5 April 2022, trading 6,447 units of SRRA stock currently worth $77,686.
Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology harnesses its deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Its team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.
Sierra Oncology Inc executives and other stock owners filed with the SEC include: